vs
Side-by-side financial comparison of Phreesia, Inc. (PHR) and Stoke Therapeutics, Inc. (STOK). Click either name above to swap in a different company.
Stoke Therapeutics, Inc. is the larger business by last-quarter revenue ($158.6M vs $120.3M, roughly 1.3× Phreesia, Inc.). Stoke Therapeutics, Inc. runs the higher net margin — 71.2% vs 3.5%, a 67.6% gap on every dollar of revenue. On growth, Stoke Therapeutics, Inc. posted the faster year-over-year revenue change (3661.1% vs 12.7%). Stoke Therapeutics, Inc. produced more free cash flow last quarter ($131.7M vs $12.2M).
Phreesia, Inc. is a software as a service company that offers healthcare organizations a set of applications to automate and manage patient intake.
Stoke Therapeutics, Inc. is a clinical-stage biotechnology company developing innovative RNA-targeted therapies for severe rare genetic diseases. Its lead candidates address unmet needs for Dravet syndrome, a rare epilepsy, and other neurological monogenic disorders, serving patients across North America and global markets.
PHR vs STOK — Head-to-Head
Income Statement — Q3 FY2026 vs Q1 FY2025
| Metric | | |
|---|---|---|
| Revenue | $120.3M | $158.6M |
| Net Profit | $4.3M | $112.9M |
| Gross Margin | — | — |
| Operating Margin | 3.1% | 70.2% |
| Net Margin | 3.5% | 71.2% |
| Revenue YoY | 12.7% | 3661.1% |
| Net Profit YoY | 129.7% | 528.0% |
| EPS (diluted) | $0.07 | $1.90 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $120.3M | — | ||
| Q3 25 | $117.3M | — | ||
| Q2 25 | $115.9M | — | ||
| Q1 25 | — | $158.6M | ||
| Q4 24 | — | $22.6M | ||
| Q2 23 | — | $-2.5M |
| Q4 25 | $4.3M | — | ||
| Q3 25 | $654.0K | — | ||
| Q2 25 | $-3.9M | — | ||
| Q1 25 | — | $112.9M | ||
| Q4 24 | — | $-10.5M | ||
| Q2 23 | — | $-30.7M |
| Q4 25 | 3.1% | — | ||
| Q3 25 | -1.3% | — | ||
| Q2 25 | -2.8% | — | ||
| Q1 25 | — | 70.2% | ||
| Q4 24 | — | -60.4% | ||
| Q2 23 | — | 1340.7% |
| Q4 25 | 3.5% | — | ||
| Q3 25 | 0.6% | — | ||
| Q2 25 | -3.4% | — | ||
| Q1 25 | — | 71.2% | ||
| Q4 24 | — | -46.4% | ||
| Q2 23 | — | 1235.6% |
| Q4 25 | $0.07 | — | ||
| Q3 25 | $0.01 | — | ||
| Q2 25 | $-0.07 | — | ||
| Q1 25 | — | $1.90 | ||
| Q4 24 | — | $-0.15 | ||
| Q2 23 | — | $-0.69 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $106.4M | $274.8M |
| Total DebtLower is stronger | $3.4M | — |
| Stockholders' EquityBook value | $320.3M | $350.1M |
| Total Assets | $423.5M | $406.9M |
| Debt / EquityLower = less leverage | 0.01× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $106.4M | — | ||
| Q3 25 | $98.3M | — | ||
| Q2 25 | $90.9M | — | ||
| Q1 25 | — | $274.8M | ||
| Q4 24 | — | $128.0M | ||
| Q2 23 | — | $192.1M |
| Q4 25 | $3.4M | — | ||
| Q3 25 | $4.6M | — | ||
| Q2 25 | $6.2M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q2 23 | — | — |
| Q4 25 | $320.3M | — | ||
| Q3 25 | $298.0M | — | ||
| Q2 25 | $282.2M | — | ||
| Q1 25 | — | $350.1M | ||
| Q4 24 | — | $229.0M | ||
| Q2 23 | — | $190.2M |
| Q4 25 | $423.5M | — | ||
| Q3 25 | $408.6M | — | ||
| Q2 25 | $400.4M | — | ||
| Q1 25 | — | $406.9M | ||
| Q4 24 | — | $271.6M | ||
| Q2 23 | — | $256.9M |
| Q4 25 | 0.01× | — | ||
| Q3 25 | 0.02× | — | ||
| Q2 25 | 0.02× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q2 23 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $15.5M | $131.8M |
| Free Cash FlowOCF − Capex | $12.2M | $131.7M |
| FCF MarginFCF / Revenue | 10.1% | 83.0% |
| Capex IntensityCapex / Revenue | 2.7% | 0.1% |
| Cash ConversionOCF / Net Profit | 3.62× | 1.17× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $15.5M | — | ||
| Q3 25 | $14.8M | — | ||
| Q2 25 | $14.8M | — | ||
| Q1 25 | — | $131.8M | ||
| Q4 24 | — | $-23.2M | ||
| Q2 23 | — | $-21.8M |
| Q4 25 | $12.2M | — | ||
| Q3 25 | $13.1M | — | ||
| Q2 25 | $11.3M | — | ||
| Q1 25 | — | $131.7M | ||
| Q4 24 | — | $-23.2M | ||
| Q2 23 | — | $-22.6M |
| Q4 25 | 10.1% | — | ||
| Q3 25 | 11.1% | — | ||
| Q2 25 | 9.8% | — | ||
| Q1 25 | — | 83.0% | ||
| Q4 24 | — | -102.7% | ||
| Q2 23 | — | 912.5% |
| Q4 25 | 2.7% | — | ||
| Q3 25 | 1.5% | — | ||
| Q2 25 | 3.0% | — | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | 0.2% | ||
| Q2 23 | — | -33.8% |
| Q4 25 | 3.62× | — | ||
| Q3 25 | 22.68× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.17× | ||
| Q4 24 | — | — | ||
| Q2 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PHR
| Subscription And Services | $55.5M | 46% |
| Network Solutions | $37.4M | 31% |
| Payment Processing Fees | $27.4M | 23% |
STOK
Segment breakdown not available.
